Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre
08 juin 2020 07h00 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of...
Dr Roch Doliveux appointed Non-Executive Chairman
01 juin 2020 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica Appoints Dr. Roch Doliveux as Non-Executive Chairman Oxford, UK – 1 June, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell...
Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for manufacture of COVID-19 vaccine candidate
28 mai 2020 07h38 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of...
Oxford Biomedica plc Preliminary results for the year ended 31 December 2019
06 mai 2020 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica plcPreliminary results for the year ended 31 December 2019 Building the Group for future growth Oxford, UK – 6 May 2020: Oxford Biomedica plc (LSE: OXB), (“OXB” or “the Group”), a...
Oxford Biomedica Interim Results
04 sept. 2019 07h00 HE
|
Oxford BioMedica plc
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2019 Oxford, UK – 4 September 2019: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell...
Oxford Biomedica notes the Japanese approval of Kymriah® (tisagenlecleucel), the first CAR-T cell therapy authorised in Asia
26 mars 2019 08h00 HE
|
Oxford BioMedica plc
Oxford Biomedica notes the Japanese approval of Kymriah® (tisagenlecleucel), the first CAR-T cell therapy authorised in Asia Oxford, UK – 26 March 2019: Oxford Biomedica plc (LSE:OXB), a leading gene...
Oxford Biomedica plc: Preliminary results for the year ended 31 December 2018
14 mars 2019 08h00 HE
|
Oxford BioMedica plc
Oxford Biomedica plcPreliminary results for the year ended 31 December 2018 Delivery of dual strategy leads to strong financial growth Oxford, UK – 14 March 2019: Oxford Biomedica plc (LSE: OXB),...
Oxford BioMedica notes that Axovant doses first patient in clinical study of AXO-Lenti-PD, a novel gene therapy for patients with Parkinson’s disease
25 oct. 2018 07h00 HE
|
Oxford BioMedica plc
Oxford BioMedica notes that Axovant doses first patient in clinical study of AXO-Lenti-PD, a novel gene therapy for patients with Parkinson’s disease Oxford, UK – 25 October 2018: Oxford BioMedica...
Oxford BioMedica announces further capacity expansion with new facility
13 sept. 2018 07h00 HE
|
Oxford BioMedica plc
Oxford BioMedica announces further capacity expansion with new facility Lentiviral vector bioprocessing market expected to grow to $800m by 2026Oxford BioMedica adds fourth facility in Oxford...
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2018
13 sept. 2018 07h00 HE
|
Oxford BioMedica plc
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2018 Oxford, UK – 13 September 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell...